Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(638)
•••
Post by floatinketuckyon Feb 17, 2022 8:38am
589 Views
Post# 34437352

FEB 7 COPR PREZ BASED OFF NOV 29 2021 DATA

FEB 7 COPR PREZ BASED OFF NOV 29 2021 DATALatest Coprate presentation FEB 7 2022 based of NOV 19 2021 data.

30 patients treated to date in the Phase II NMIBC clinical study 32 3 patients treated in the Phase Ib NMIBC clinical study Total population of 33 patietheralase.com/wp-content/up...nts 5 clinical study sites open in Canada and 7 in United States
Feb 7 2022 copr prez 33 total patients treated (3 from phase one) NO NEW REPORTING FROM 29 NOV 2021!!!
_

From the last quarterly newsletter. 3Q2021 | NOVEMBER 2021

Study II Status:
Theralase® has enrolled and treated 30 patients in a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study II") (including three patients from the Phase Ib NMIBC clinical study (“Study”) treated at the Therapeutic Dose) for a total of 33 patients.
last quarterly newsletter
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities